Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025

Reuters

昨天

Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has announced the completion of patient dosing in its Phase 1 clinical trial of an oral transmucosal fast-acting high-dose aspirin formulation. The trial, conducted in the United States, aims to compare the pharmacokinetic and pharmacodynamic characteristics of the aspirin formulation in healthy volunteers. Topline results from the study are expected to be presented in the middle of the third quarter of 2025. The company plans to use these insights to further discussions with the FDA and to support potential partnership opportunities. Following the trial, Aspire intends to submit a section 505(b)(2) NDA for approval to market the high-dose aspirin product.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042140) on June 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545282793"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545282793\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545282793?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545282793","market":"nz","top_or_hot":-1,"title":"Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has announced the completion of patient dosing in its Phase 1 clinical trial of an oral transmucosal fast-acting high-dose aspirin formulation. The trial, conducted in the United States, aims to compare the pharmacokinetic and pharmacodynamic characteristics of the aspirin formulation in healthy volunteers. Topline results from the study are expected to be presented in the middle of the third quarter of 2025. The company plans to use these insights to further discussions with the FDA and to support potential partnership opportunities. Following the trial, Aspire intends to submit a section 505(b)(2) NDA for approval to market the high-dose aspirin product.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ASBP\">Aspire Biopharma Holdings Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042140) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-24 20:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has announced the completion of patient dosing in its Phase 1 clinical trial of an oral transmucosal fast-acting high-dose aspirin formulation. The trial, conducted in the United States, aims to compare the pharmacokinetic and pharmacodynamic characteristics of the aspirin formulation in healthy volunteers. Topline results from the study are expected to be presented in the middle of the third quarter of 2025. The company plans to use these insights to further discussions with the FDA and to support potential partnership opportunities. Following the trial, Aspire intends to submit a section 505(b)(2) NDA for approval to market the high-dose aspirin product.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ASBP\">Aspire Biopharma Holdings Inc.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042140) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ASBP","symbol_name":"Aspire Biopharma Holdings Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL1Y2Sk1:1","article_id":"2545282793","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545282793","pubTimestamp":1750768247,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025. Aspire Biopharma Holdings, Inc.  has announced the completion of patient dosing in its Phase 1 clinical trial of an oral transmucosal fast-acting high-dose aspirin formulation. The trial, conducted in the United States, aims to compare the pharmacokinetic and pharmacodynamic characteristics of the aspirin formulation in healthy volunteers. Topline results from the study are expected to be presented in the middle of the third quarter of 2025. The company plans to use these insights to further discussions with the FDA and to support potential partnership opportunities. Following the trial, Aspire intends to submit a section 505 NDA for approval to market the high-dose aspirin product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ASBP":"Aspire Biopharma Holdings Inc.","BK4007":"制药"},"translate_title":"Aspire Biopharma Holdings完成速效大剂量阿司匹林1期试验的患者给药，预计2025年第三季度中期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASBP":0.9},"content_text":"Aspire Biopharma Holdings Completes Patient Dosing in Phase 1 Trial of Fast-Acting High-Dose Aspirin, Results Expected Mid Q3 2025\n    \n\n        Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) has announced the completion of patient dosing in its Phase 1 clinical trial of an oral transmucosal fast-acting high-dose aspirin formulation. The trial, conducted in the United States, aims to compare the pharmacokinetic and pharmacodynamic characteristics of the aspirin formulation in healthy volunteers. Topline results from the study are expected to be presented in the middle of the third quarter of 2025. The company plans to use these insights to further discussions with the FDA and to support potential partnership opportunities. Following the trial, Aspire intends to submit a section 505(b)(2) NDA for approval to market the high-dose aspirin product.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1042140) on June 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}